Needham & Company Upgrades Hologic (HOLX) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- SK Hynix’s record plunge drags down global chip stocks
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Leerink Partners Remains Bullish on Hologic (HOLX) as Lower Tax Rate Helps Drive 1Q Results
January 28, 2016 9:31 AM ESTLeerink Partners maintained an Outperform rating on Hologic (NASDAQ: HOLX), and cut the price target to $44.00 (from $47.00), following the company's 1Q earnings report. HOLX reported revenue of $695M, which was $6M ahead of the Street's estimate, with outperformance primarily from GYN and... More
Hologic (HOLX) Tops Q1 EPS by 4c; Guides FY EPS Higher
January 27, 2016 4:07 PM ESTHologic (NASDAQ: HOLX) reported Q1 EPS of $0.46, $0.04 better than the analyst estimate of $0.42. Revenue for the quarter came in at $695.2 million versus the consensus estimate of $688.04 million.
GUIDANCE:
Hologic sees Q2 2016 EPS of $0.45-$0.46, versus the consensus of $0.45. Hologic sees Q2... More
